MiR-181b targets BCL2, MCL1 and TCL1 genes in CLL [35,54,55] and thus its potential as a therapeutic agent was tested in a CLL mouse model. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.